Epcoritamab for DLBCL

 

When Hope Ran Out: The Crisis in Relapsed Lymphoma

By the late 2010s, oncologists treating patients with relapsed or refractory large B-cell lymphoma faced a grim reality. For patients whose disease had stopped responding to chemotherapy, the outlook was dire. The landmark SCHOLAR-1 study had quantified this desperation: patients with refractory diffuse large B-cell lymphoma (DLBCL) responded to subsequent treatment only 26% of the time, with a mere 7% achieving complete remission. Median survival was 6.3 months.

Then came CAR T-cell therapy, a revolutionary approach that genetically engineers a patient's own immune cells to hunt down cancer. It was transformative—offering durable remissions to 30-40% of patients who had no other options. But CAR T brought its own complications. Manufacturing required weeks of waiting while harvesting, engineering, and expanding cells. Many patients with aggressive disease progressed or died before their customized treatment was ready. Others couldn't access the therapy at all due to fitness requirements, geographic barriers, or simply being too sick to survive the process.

And for those who relapsed after CAR T? The prognosis was catastrophic—median survival of roughly five to six months, with no established salvage therapy. These patients existed in a therapeutic no-man's-land, having exhausted every standard option. They needed a "Hail Mary."

Enter Epcoritamab: A Different Approach to Immunotherapy

The EPCORE NHL-1 trial (NCT03625037) was designed to test whether a fundamentally different approach could rescue these patients. Instead of harvesting and engineering T cells outside the body, epcoritamab works by redirecting the patient's existing T cells to attack cancer cells directly in the body. It's a bispecific antibody—a Y-shaped protein that binds to two different targets simultaneously. One arm grabs CD3 on T cells; the other grabs CD20 on malignant B cells. By bridging these cells together, epcoritamab creates an artificial immunological synapse, triggering T cells to destroy the cancer without requiring any genetic modification or cell manufacturing.

But what made epcoritamab particularly innovative was its subcutaneous delivery. Rather than requiring intravenous infusion, it's injected under the skin like insulin. This creates a "depot effect"—the drug absorbs gradually into the bloodstream rather than hitting as a sudden spike. The trial designers hypothesized this would translate into a gentler safety profile, particularly for cytokine release syndrome (CRS), the sometimes-dangerous inflammatory reaction that accompanies T-cell activation.

The Trial Design: Learning to Walk Before Running

EPCORE NHL-1 began with a careful dose-escalation phase, testing doses ranging from microscopic amounts (0.0128 mg) up to 60 mg. The critical innovation was "step-up dosing"—rather than hitting patients with a full therapeutic dose immediately, the protocol introduced the immune system to epcoritamab gradually. On Day 1, patients received a tiny priming dose of 0.16 mg. On Day 8, an intermediate dose of 0.8 mg. Only on Day 15 did they receive the first full dose of 48 mg.

This careful ramp-up proved crucial. In the dose-escalation phase, while 59% of patients experienced some degree of CRS, every single case was grade 1 or 2—manageable symptoms like fever and fatigue. No life-threatening reactions occurred. The step-up approach had successfully uncoupled potent anti-cancer activity from severe toxicity.

With 48 mg established as the recommended dose, the trial expanded to treat a larger cohort of LBCL patients—157 individuals who represented the toughest cases in lymphoma. Their median age was 64. They had received a median of three prior treatment lines. Sixty-one percent had never responded to first-line therapy (primary refractory disease). And crucially, 39% had already received and failed CAR T-cell therapy.

The Results That Changed Everything

When Dr. Catherine Thieblemont presented the interim results at the European Hematology Association congress in June 2022, the response was immediate. The numbers were extraordinary for this population: 63% of patients responded to epcoritamab, with 39% achieving complete remission. For context, the historical expectation in similar patients was around 26% response with 7% complete remission.

But the truly jaw-dropping data came from the CAR T-failure subgroup. These were patients who had been given what many considered the last-resort option and had relapsed. Conventional wisdom held that their T cells were "exhausted"—incapable of mounting effective anti-cancer responses. Yet epcoritamab achieved a 54% response rate with 34% complete remissions in this supposedly untreatable population.

This finding shattered the exhaustion dogma. It demonstrated that T cells could still be redirected to kill tumors even after CAR T failure, suggesting that CAR T relapses often result from CAR-specific mechanisms rather than fundamental T-cell dysfunction. For patients who had been told nothing more could be done, there was suddenly a new option.

Durability: Not Just Responses, But Lasting Remissions

Early responses are encouraging, but what matters most is whether they last. Here, epcoritamab continued to impress. The median duration of response was 12 months across all responders. For patients achieving complete remission, the median duration wasn't reached—meaning more than half were still in remission when the study was analyzed. At the nine-month mark, 89% of complete responders remained in remission.

Longer-term follow-up has reinforced these findings. At two years, approximately 64% of complete responders remained in remission. By three years, patients who had maintained complete remission at the two-year mark showed exceptional stability—roughly 96% were still in remission at three years. This plateauing of the survival curve suggests that for a meaningful subset of patients, epcoritamab may be inducing something approaching functional cure.

A Safety Profile That Enabled Outpatient Treatment

Potency means nothing if toxicity prevents treatment. Here, the subcutaneous delivery and step-up dosing paid dividends. CRS occurred in about 50% of patients, but almost all cases were grade 1 or 2. Only 2.5% experienced grade 3 CRS, and there were no grade 4 or 5 events. Neurotoxicity (ICANS), which can be devastating with CAR T therapy, was rare—occurring in about 6% of patients, mostly mild.

Critically, these adverse events followed a predictable pattern. CRS almost exclusively occurred during the first cycle, typically within 24-48 hours of the first full dose. After patients cleared this window, the risk largely disappeared. This temporal predictability meant that after brief monitoring during cycle 1, treatment could continue on an outpatient basis—a dramatic contrast to CAR T therapy, which often requires weeks of hospitalization.

From Trial to Treatment: Regulatory Approvals

The strength of the EPCORE NHL-1 data translated rapidly into regulatory action. In May 2023, the FDA granted accelerated approval for epcoritamab (marketed as Epkinly) in adults with relapsed or refractory DLBCL or high-grade B-cell lymphoma after two or more prior lines of therapy. The approval specifically cited the 61% response rate and 38% complete remission rate as evidence of meaningful clinical benefit.

The regulatory footprint continued expanding. A separate cohort within EPCORE NHL-1 tested epcoritamab in follicular lymphoma, achieving an impressive 82% response rate with 62.5% complete remissions. This led to FDA approval for relapsed/refractory follicular lymphoma in 2024. By November 2025, the combination of epcoritamab with rituximab and lenalidomide received full approval for follicular lymphoma based on phase 3 data showing a 79% reduction in the risk of progression or death compared to standard therapy.

What This Means for Patients

The emergence of epcoritamab represents a fundamental shift in how we approach relapsed B-cell lymphoma. It offers a potent immunotherapy option without the manufacturing delays of CAR T. It can salvage patients who have failed CAR T. It can be administered largely on an outpatient basis. And it's immediately available—no need to wait weeks for cell engineering.

This doesn't mean epcoritamab replaces CAR T therapy; the two approaches serve complementary roles. But for patients who can't access CAR T, who can't wait for manufacturing, or who have already failed CAR T, epcoritamab provides hope where previously there was none.

The EPCORE NHL-1 trial transformed what was once a "Hail Mary" experimental approach into a validated treatment option. In doing so, it demonstrated that the therapeutic ceiling for relapsed lymphoma hasn't been reached—and that innovative drug design can continue pushing it higher.

---

This post synthesizes findings from the EPCORE NHL-1 trial as published in the Journal of Clinical Oncology (Thieblemont et al., 2023), with additional data from conference presentations at ASH and EHA, and FDA approval documentation. The trial remains ongoing with extended follow-up analyses continuing to refine our understanding of long-term outcomes.

Key Statistics from EPCORE NHL-1 (LBCL Cohort):

• Overall Response Rate: 63%
• Complete Response Rate: 39%
• Median Duration of Response: 12 months
• Response Rate in Post-CAR T Patients: 54%
• Grade 3+ CRS: 2.5%

Evidence Update and Context Addendum

Since the original version of this post, additional trial reports, regulatory documents, and real‑world data have refined several numerical estimates and clarified some mechanistic and practical interpretations of epcoritamab’s use in relapsed/refractory large B‑cell lymphoma and follicular lymphoma. 

The following points do not overturn the core conclusions or the main efficacy and safety signals described above; instead, they provide tighter ranges, updated follow‑up, and clearer caveats where earlier wording may have sounded more definitive than the underlying evidence supports. 

• CAR T durable remission rate (30–40%). Long-term durable remission rates after CAR T vary by product, line of therapy, and follow-up; some trials show higher complete response and durability in selected groups, so “30–40%” is an approximation rather than a precise, universal figure.
• Post–CAR T survival (5–6 months). Median overall survival after relapse from CAR T is very poor and often measured in months, but published estimates differ by cohort and product; “5–6 months” should be treated as an order-of-magnitude estimate, not a single agreed-on number.

• Subcutaneous ‘depot effect’ and CRS safety. Subcutaneous epcoritamab with step-up dosing clearly mitigates CRS severity, but the described “depot effect” is a mechanistic hypothesis rather than a directly measured clinical endpoint, so it should be framed as explanatory rather than definitive.
• 59% CRS, all grade 1–2, no life-threatening events (dose-escalation phase). Overall EPCORE NHL‑1 data show CRS in about 50% of patients with ~2.5% grade ≥3 CRS, meaning some higher-grade events occurred; any 59%/all grade 1–2 statement applies only to a specific early cohort and should not be generalized to the entire study.
• Duration of response: 12 months overall, 89% of CRs in remission at 9 months. Later analyses show median DOR closer to 15–20 months and different Kaplan–Meier estimates for CR durability; the 12‑month median and 89% figure come from earlier data cuts and are now somewhat outdated.
• Two- and three-year CR durability (64% at 2 years; 96% of those still in CR at 2 years remain in CR at 3 years). Long-term follow-up confirms a plateau with many CRs ongoing beyond 2–3 years, but the exact percentages depend on the specific analysis set and cutoff; these numbers should be labeled as approximate Kaplan–Meier estimates rather than fixed probabilities.
• CRS timing: 24–48 hours and risk ‘largely disappears’ afterward. CRS is concentrated in cycle 1 and is most common around the first full dose, but cases can occur outside a strict 24–48 hour window; saying risk “largely disappears” oversimplifies a pattern that remains possible, though less frequent, in later cycles
• CAR T failure mechanism and ‘exhaustion dogma.’ Robust responses to epcoritamab after CAR T relapse show that T cells can still be pharmacologically redirected, but attributing CAR T failure primarily to CAR-specific mechanisms and rejecting “exhaustion” as a major driver is an interpretation that goes beyond what EPCORE NHL‑1 was designed to prove.
• FDA approval timing: epcoritamab FL approval in 2024. Epcoritamab received accelerated approval for relapsed/refractory FL based on NHL‑1 data, with regulatory milestones spread across late 2024 and 2025; the post should specify that 2024 refers to the initial FL indication, with subsequent label expansions and conversions following later.
• Outpatient vs inpatient framing (epcoritamab vs CAR T). Epcoritamab is predominantly delivered in outpatient settings with short-term monitoring, while many CAR T programs still rely on planned inpatient observation; however, some centers now deliver CAR T partly outpatient, and some epcoritamab patients are monitored or admitted early, so the contrast should be described as “often” rather than absolute.